Juan Tortajada Valero

Juan Tortajada Valero

Auto-generated profile, based on publicly available information

Juan Tortajada Valero

Hospital Universitari Institut Pere Mata (HUIPM) Reus Catalonia Spain

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Psychiatry Research
Verified
Journal Article
Open access
BBBengisu K. Bulduk
Bengisu K. Bulduk
JTJuan Tortajada
Juan Tortajada
AVAlba Valiente-Pallejà
Alba Valiente-Pallejà
LCLuis Callado
Luis Callado
Helena TorrellHelena Torrell
Helena Torrell
Lourdes MartorellLourdes Martorell
Lourdes Martorell
Previous studies have shown mitochondrial dysfunction in schizophrenia (SZ) patients, which may be caused by mitochondrial DNA (mtDNA) alterations. However, there are few studies in SZ that have analyzed mtDNA in brain samples by next-generation sequencing (NGS). To address this gap, we used mtDNA-targeted NGS and qPCR to characterize mtDNA alterations in brain samples from patients with SZ (n = 40) and healthy controls (HC) (n = 40). 35 % of SZ patients showed mtDNA alterations, a significantly higher prevalence compared to 10 % of HC. Specifically, SZ patients had a significantly higher frequency of deletions (35 vs. 5 in HC), with a mean number of deletions of 3.8 in SZ vs. 1.0 in HC. Likely pathogenic missense variants were also significantly more frequent in patients with SZ than in HC (10 vs. three HC), encompassing 14 variants in patients and three in HC. The pathogenic tRNA variant m.3243A>G was identified in one SZ patient with a high heteroplasmy level of 32.2 %. While no significant differences in mtDNA copy number (mtDNA-CN) were observed between SZ and HC, antipsychotic users had significantly higher mtDNA-CN than non-users. These findings suggest a potential role for mtDNA alterations in the pathophysiology of SZ that require further validation and functional studies.

1 June 2026 in General Psychiatry
Verified
Journal Article
Open access
JTJuan Tortajada
Juan Tortajada
BBBengisu Kevser Bulduk
Bengisu Kevser Bulduk
BABelén Alfonso‐Landete
Belén Alfonso‐Landete
PAPaula Alcaide‐Barriga
Paula Alcaide‐Barriga
BBBernat Ballvé‐Gelonch
Bernat Ballvé‐Gelonch
Lourdes MartorellLourdes Martorell
Lourdes Martorell
Background: Nutraceutical supplementation targeting mitochondrial function has been proposed as a beneficial therapeutic strategy to improve physical and mental health in psychiatric patients. Aims: To summarise the results of studies evaluating nutraceutical supplementation targeting mitochondrial function in patients with psychiatric disorders. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines, we searched PubMed, Embase and Scopus databases from 1 January 2007 to 30 April 2024. Reports were included if they evaluated outcomes of nutraceutical supplementation in patients with psychiatric disorders or related conditions. Additionally, we performed a risk‐of‐bias analysis of the studies compatible with the RoB2 tool. Results: Of the 2061 records identified, 122 studies met the inclusion criteria, evaluating vitamin D3, N‐acetylcysteine, acetyl‐L‐carnitine, coenzyme Q10, alpha‐lipoic acid, magnesium, vitamin B6, vitamin B7, folic acid, vitamin B12, vitamin E, vitamin A, vitamin C and vitamin B3. The most studied nutraceuticals were vitamin D3 (27.05%) and N‐acetylcysteine (15.6%). Among randomised controlled clinical trials (RCTs), vitamin D3 was the most extensively investigated and accounted for the highest number of trials reporting improvements in clinical outcomes, although findings were heterogeneous. Notably, 14.8% of the studies evaluated combinations of three or more nutraceuticals. Dietary supplements were extensively evaluated for autism spectrum disorder (28 studies), schizophrenia spectrum disorder (27 studies), major depressive disorder or related depressive symptoms (22 studies), attention‐deficit hyperactivity disorder (9 studies) and bipolar spectrum disorder (6 studies). A substantial proportion of studies were not RCTs but open‐label single‐arm trials or case reports. Significant heterogeneity was observed in the nutraceutical components used, treatment duration and the outcomes assessed. Overall, the risk of bias was high, and the methodological quality was generally low. Conclusions: Promising findings in nutraceutical studies for psychiatric disorders face challenges, including small sample sizes, short follow‐up periods and a lack of treatment standardisation. Future research requires robust RCTs with standardised protocols and validated biomarkers of efficacy.

27 September 2021 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
BBBengisu Bulduk
Bengisu Bulduk
LTLeire Torres-Egurrola
Leire Torres-Egurrola
JVJuan Tortajada Valero
Juan Tortajada Valero
AVAlba Valiente-Pallejà
Alba Valiente-Pallejà
Helena TorrellHelena Torrell
Helena Torrell
GMGerard Muntane
Gerard Muntane

1 October 2021 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
JVJuan Tortajada Valero
Juan Tortajada Valero
BBBengisu Bulduk
Bengisu Bulduk
AVAlba Valiente-Pallejà
Alba Valiente-Pallejà
EVElisabet Vilella
Elisabet Vilella
GMGerard Muntane
Gerard Muntane
Lourdes MartorellLourdes Martorell
Lourdes Martorell

1 March 2011 in European Psychiatry
Verified
Journal Article
Closed access
LML. Moreno
L. Moreno
JVJ. Valero
J. Valero
AGAna M. Gaviria Gómez
Ana M. Gaviria Gómez
ALA. Labad
A. Labad
Introduction: Impaired sustained and selective attention have been seen as vulnerability factors to psychotic disorders. Relatives of psychotic patients are a risk population for psychosis, and previous studies have shown that they displayed more attentional deficits compared with healthy controls. Additionally, relatives have more pathological personality and schizotypy, the least considered also to be the expression of the genetic vulnerability to schizophrenia. There are few studies that relate attention to personality factors in relatives of psychotic patients.Aims: To compare attentional performance of siblings of psychotic patients with those of healthy controls, taking into account their pathological and schizotypal personality.Methods: The Spanish version of the SPQ and the DAPP-BQ were administered to a sample of 51 subjects that were divided into four groups by a hierarchical cluster analysis: siblings with high pathological personality (SHPP), siblings with low pathological personality (SLPP), controls with high pathological personality (CHPP), and controls with low pathological personality (CLPP). In all the subjects we assessed a sustained attention index (SUA) and a selective attention index (SEA). We compared the performance of the four groups on these attentional indexes.Results: We found that SHPP had worse performance on sustained attention compared with CLPP. Specifically this difference was in the reaction time item of the SUA.Conclusions: The high schizotypy and pathological personality had an influence on sustained attentional performance in the siblings of patients with psychosis, but not in the healthy controls.